Literature DB >> 17624687

Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.

Nicholas Lintzeris1, Timothy B Mitchell, Alyson J Bond, Liam Nestor, John Strang.   

Abstract

BACKGROUND: Benzodiazepine abuse is common among methadone- and buprenorphine-maintained patients; however interactions between these drugs under high dose conditions have not been adequately examined under controlled conditions.
OBJECTIVE: To investigate the effects of co-administering diazepam with methadone or buprenorphine under high dose conditions.
DESIGN: Double-blind, randomly ordered, 2 x 2 cross-over design in which the effects of diazepam dose (0mg versus 40 mg) and opioid dose (100% versus 150% normal dose) were examined over four sessions in methadone- and buprenorphine-maintained patients. PARTICIPANTS: Four methadone- and seven buprenorphine-prescribed patients without concurrent dependence on other substances or significant medical co-morbidity. MEASURES: Physiological (pulse rate, blood pressure, pupil size, respiratory rate and peripheral SpO2), subjective (ARCI, VAS ratings) and performance (reaction time, cancellation task and Digit Symbol Substitution Test, DSST) measures were taken prior to and for 6h post-dosing.
RESULTS: High dose diazepam was associated with time-dependent increases in the intensity of subjective drug effects (strength of drug effect, sedation) and decreases in psychological performance (reaction time, DSST) for both methadone and buprenorphine patients. These effects were generally independent of the opioid dose administered. High dose opioid administration (150% normal dose) was associated with reductions in overall SpO2 levels and performance (reaction time, DSST) in the methadone patients, but had virtually no impact on pharmacodynamic responses in the buprenorphine group.
CONCLUSION: High dose diazepam significantly alters subjective drug responses and psychological performance in patients maintained on methadone and buprenorphine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624687     DOI: 10.1016/j.drugalcdep.2007.05.019

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  23 in total

1.  Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers.

Authors:  Bethea A Kleykamp; Ryan G Vandrey; George E Bigelow; Eric C Strain; Miriam Z Mintzer
Journal:  Am J Drug Alcohol Abuse       Date:  2015-01-13       Impact factor: 3.829

2.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

Review 3.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 4.  Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.

Authors:  Jag H Khalsa; Ahmed Elkashef
Journal:  Am J Addict       Date:  2010 Jan-Feb

5.  Increasing availability of benzodiazepines among people who inject drugs in a Canadian setting.

Authors:  Geoffrey Walton; Huiru Dong; M J Milloy; Kora DeBeck; Thomas Kerr; Evan Wood; Kanna Hayashi
Journal:  Subst Abus       Date:  2017-09-18       Impact factor: 3.716

6.  Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder.

Authors:  R Kathryn McHugh; Victoria R Votaw; Olivera Bogunovic; Sterling L Karakula; Margaret L Griffin; Roger D Weiss
Journal:  Addict Behav       Date:  2016-08-18       Impact factor: 3.913

Review 7.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

8.  Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.

Authors:  Richard Hallinan; Séverine Crettol; Kingsley Agho; John Attia; Jacques Besson; Marina Croquette-Krokar; Robert Hämmig; Jean-Jacques Déglon; Andrew Byrne; John Ray; Andrew A Somogyi; Chin B Eap
Journal:  Eur J Clin Pharmacol       Date:  2009-07-29       Impact factor: 2.953

9.  The Impact of Benzodiazepine Use on Mortality Among Polysubstance Users in Vancouver, Canada.

Authors:  Geoffrey R T Walton; Kanna Hayashi; Paxton Bach; Huiru Dong; Thomas Kerr; Keith Ahamad; M J Milloy; Julio Montaner; Evan Wood
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

Review 10.  Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use.

Authors:  Jeffrey A Gudin; Shanthi Mogali; Jermaine D Jones; Sandra D Comer
Journal:  Postgrad Med       Date:  2013-07       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.